CNBC's "Fast Money" Down Day For Drugmakers… And Intel Jumps On Deal Rumors 1/17/25
12 snips
Jan 17, 2025 Dr. Kavita Patel, a medical contributor at NBC News and MSNBC, dives into the recent turmoil in the pharmaceutical industry, especially as Novo Nordisk's shares hit an 18-month low due to new Medicare price negotiations. She discusses the implications for the weight loss drug market and investor concerns about healthcare under changing political conditions. On another note, she speculates about Intel's stock surge driven by M&A rumors and what potential deals could mean for the tech sector.
AI Snips
Chapters
Transcript
Episode notes
Novo Nordisk's Challenges
- Dr. Kavita Patel discusses Novo Nordisk's challenges, including Medicare negotiations and trial results.
- She mentions the potential game-changing nature of Eli Lilly's retatrutide.
Eli Lilly's Positioning
- Novo Nordisk faces challenges with semaglutide's patent expiration and Eli Lilly's competing drug.
- Eli Lilly is well-positioned in the chronic disease market due to its pipeline and drug efficacy.
Trump's Crypto Focus
- President-elect Trump is prioritizing crypto, potentially issuing a crypto-specific executive order.
- This includes plans for a crypto advisory council and a national Bitcoin stockpile.